January 2015 Product Preview: FDA committee recommends approval of complicated UTI agent
December 31st 2014Drugs and devices in the pipeline from Actavis, Genomic Health, Lipella Pharmaceuticals, Polaris Group, Innocrin Pharmaceuticals, OncoGenex Pharmaceuticals, Heat Biologics, Repros Therapeutics, and Sophiris Bio.
2014 Year in Review: Prostate Cancer
December 16th 2014With emergence of new biomarker and tests, high-profile approvals of treatments for new indication, and the ongoing controversy surrounding PSA screening, prostate cancer remained very much in the urology headlines for 2014. Here are some of the most-read Urology Times articles on the disease.
Prostate Ca assays show economic, clinical benefits
December 5th 2014The Prolaris prostate cancer test could save the health care system $6 billion over 10 years, according to data from one of several new studies examining the economic and clinical benefits of newer biomarker-based prostate cancer assays.
Prostate Ca test accurately predicts high-grade disease
November 19th 2014Results from the U.S. validation study of a test that combines plasma levels of four prostate-specific kallikreins with clinical data demonstrated it accurately predicts high-grade prostate cancer and is superior to a validated clinical variable-based risk calculator.
New biomarkers address key aspects of prostate Ca management
November 6th 2014New biomarkers for prostate cancer are showing great promise for addressing the limitations of existing diagnostic and prognostic tools, according to opinion leaders who spoke on this topic at the Large Urology Group Practice Association annual meeting in Chicago.
MRI-targeted prostate biopsy offers four fundamental benefits
November 6th 2014Magnetic resonance imaging (MRI) is a promising tool for optimizing prostate cancer biopsy that appears to overcome the shortcomings of conventional systematic transrectal ultrasound (TRUS)-guided biopsy and also provides novel information for risk stratification that can guide the decision of whether to perform biopsy, according to Samir Taneja, MD.
Most websites disagree with PCa screening recommendation
November 3rd 2014A vast majority of top-ranked consumer health websites disagree with the U.S. Preventive Services Task Force’s recommendation against screening for prostate cancer, according to a study presented at the American College of Surgeons clinical congress in San Francisco.